The management and treatment of patients with advanced unresectable hepatocellular carcinoma (HCC)
Description
How do you manage and treat your patients with advanced unresectable HCC? Watch as experts Dr David Pinato and Dr Rohini Sharma discuss what they would consider in this educational video. See them talking about the evolving treatment landscape of advanced HCC, guidance on key treatment considerations and appropriate treatment selection for advanced HCC patients plus their recommendations for potentially maximising treatment benefits. Their discussion can be watched as a complete video and has also been divided into easy to watch, short clips below.
Chapter 2: Key Treatment Considerations
Chapter 3: Maximising treatment benefits
Speakers
Dr David Pinato
Dr David Pinato is a Clinician Scientist and Consultant Medical Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working within the Department of Surgery and Cancer at Imperial College, London. Dr Pinato leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented David’s focus of research since graduation.
Dr Rohini Sharma
Dr Rohini Sharma is a Reader in Clinical Pharmacology and Medical Oncology. She is also a Consultant Medical Oncologist based at the Hammersmith Hospital campus of Imperial College Healthcare NHS Trust. Her clinical and research interests are in HCC, Neuroendocrine tumours (NETs) and development of novel biomarkers. To this end, Dr Sharma is the Oncology lead for the specialist Hepato-Oncology Clinic, a unique service where patients are jointly managed by a Hepatologist and Medical Oncologist with a view to improving clinical outcomes and promoting research. She is the lead of the liver cancer research group at Imperial and also the Oncology lead for the management of NETs within the Trust.
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
